Member Info for Cuddles48

2020 hasn't been a year for many celebrations and we were just going to let this one slide... but as the year draws to a close and so much hope is now on the horizon, we thought it only right to wish ourselves a big Happy 20th Birthday!

20 years ago we never envisaged that we would ever be where we are now - publicly listed (3 years today!), 200+ humanizations, 11+ clinical trials and 50+ staff (to list but a few). We could never have hoped or dreamed to have the achievements and successes that the past 2 decades have brought us.

It has been a steep learning curve, one which we continue to climb each and every day. We would like to take the opportunity to thank each and every person and organisation that has been on this journey with us and that has given us the support and encouragement to continue to succeed and grow - it is because of you all that we are the FAB company that we are.

#20yearsinbusiness #20years #success #celebratingsuccess #celeb

https://welpmagazine.com/top-health-diagnostics-companies-and-startups-in-the-uk/

Adam Stallone
Why did you invest £1000 in the first place.

If you liked it at £2 you should love love love it at £1.30. You should treble or more up so as to benefit when it eventually goes to £30 which is the value the shares will be when as Paul Kerr stated that the Mamalian antibody library they are building should be worth in two to three years time.

Do you want to make a killing if so fill your boots lock it away and wait two to three years

Is this another clue as to who they may have a collaboration with ?

Feel good Friday - and another breakthrough in the world of science today to make a better tomorrow...

This week Calypso Biotech have announced that they are in clinical trials to evaluate an experimental new treatment in the fight again Celiac Disease and Eosinophilic Esophagitis.

Good luck to all the team at Calypso at this exciting time!

https://bit.ly/3lQJ5hZ

#CDRx #humanization #antibodydevelopment #humanisation #antibodies #drugdiscovery #drugdevelopment #success #clinicaltrials #antibodydrugs

Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin- 15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases
Dose -escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis
Amsterdam, The Netherlands, 16 November 2020. Calypso Biotech, a company developing Interleukin-15-targeted biologics, today announced completion of dosing of first cohort of healthy subjects in the first Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15.
“CALY-002 is the lead program of our differentiated pipeline of IL-15-targeting biologics, that we plan to investigate in multiple auto-immune diseases. CALY-002 has an unique mode of action which translates into potent biological activity in vivo and is expected to show superior clinical efficacy in patients”, says Alain Vicari DVM, PhD, Chief Executive Officer of Calypso Biotech. “IL-15 is a key target in auto-immune diseases. IL-15 controls unique immune pathways such as Natural Killer cells and Memory T cells critically involved in disease onset and maintenance, as well as tissue destruction, in addition to its broad effect on inflammation”, adds Yolande Chvatchko PhD, Chief Scientific Officer of Calypso Biotech.
Calypso Biotech has elected Celiac Disease and Eosinophilic Esophagitis to evaluate the biological and clinical efficacy of CALY-002. Celiac Disease and Eosinophilic Esophagitis are two diseases with high unmet medical need where IL-15 causes inflammation, and tissue destruction. “I am excited that this trial will inform about the safety, pharmacokinetic and pharmacodynamic of single and multiple administrations with CALY-002 in highly relevant populations.” comments Josefin-Beate Holz, MD, Chief Medical Officer of Calypso Biotech.
More information on the trial can be found:
https://clinicaltrials.gov/ct2/show/NCT04593251
About Celiac Disease and IL-15
Celiac Disease is a serious autoimmune disease that occurs in genetically predisposed people where the ingestion of gluten, a protein found in wheat, barley, and ryeand derived products, leads to damage in the small intestine. It is estimated to affect 1 in 100 people worldwide. Celiac Disease can cause symptoms including abdominal pain, diarrhea, nausea, and vo

Using our CDRx™? platform, we provide our clients with a 25-variant panel of humanized antibodies that retain the affinity of the parent antibody and those that are development-ready. At least a third of antibodies (8 molecules from 33 projects) from our earlier humanization projects have entered clinical trials.

#antibodies #research #innovation #antibodytesting #humanization #antibody #innnovation #clinicaltrials #clinicalstudies #clinicaltrial #clinicaldevelopment #discovery #drugdiscovery

Now have 25 molecules with carry fee so even more chance of regular annual incomes and milestone payments.

Yes still waiting for Mismis to fez up on what he has heard are the many negatives he talks about.

We are waiting to openly discuss.

Can you elaborate on the negatives you have heard about so we can discuss as you requested.

I can’t think of any that jump to mind.

Recruiting fully funded from early fund raise steadily rising revenue, multiple potential windfall payments from carries in clinical trials.

We are hiring!

We are currently recruiting for two exciting roles to join our FAB-ulous team based in Belfast.

1. Laboratory Technician Post: https://bit.ly/3mMeH9i
2. Graduate Scientist - Antibody Discovery: https://bit.ly/2L7guHX

If you think you have what it takes to join the Fusion Family, click on the links above for more details on the roles and how to apply. Closing dates for both is Friday 18th December 2020.

Good Luck!

#newjobopportunities #newcareeropportunities #newcareer #newbeginnings #jobannouncement #jobadvertisement #jobhunt2020 #careeropportunity #careeropportunities #nowhiring #jobhunt #sciencejobs #hiring

Bugger me despite all my best efforts to help people see what is being developed in front of investors eyes no one appart feom me And Djryan are buying this.

I have built up a 2.5% holding taking that stock out of circulation. market makers must be getting rather ****ed off with me as there is no way they have replaced the stock I have purchased from sellers.

They are trying all the usual tactics of stopping the price to scare out sellers. Nearly always works for them. But I keep buying making there travails pointless.

If more long term holders and new investors dipped in and bought some more stock the market makers would have no choice but to raise the bid as there is no way they are going to get bailed out with a cheap placing. The company does not need short term cash !!!!

Buy and hold and wait for your just rewards

Please help me take out the city !!!

Fusion Antibodies has been on an amazing journey in such a short time, and that is largely due to the help and support of QUBIS Ltd - we are immensely proud of our long standing heritage with Queen's University Belfast and certainly weren't surprised to read that they have come out on top (once again) in the Octopus Ventures Entrepreneurial Impact report - "QUB’s success emphasises the importance of quality of spinout – it consistently yields a high proportion of successful exits."

#success #spinout #innovation #research

https://lnkd.in/dYcAg4v

Its interesting to see some more of the info regarding FABs £233k Contract Award Notice as pointed out by matheus7777 below. hTTps://bidstats.uk/tenders/2020/W48/739573847 Legal Justification The direct award contract is requested to allow the development and manufacture of a new therapeutic drug for Covid-19 that is funded by DfE. The project therefore falls under the PPN 01/20 guidelines. This project is part of a rapid Covid SFI response call where there is an urgency to develop new therapies and solutions to tackle the current Covid-19 pandemic. A research agreement has been developed between Ulster University, Fusion Antibodies, Queens University Belfast (QUB) and Trinity College Dublin in the delivery of this Covid project. It is important that Fusion Antibodies remain the developer and supplier of this drug to avoid drug batch variation. Batch effects could represent systematic technical differences in results obtained between studies. This could lead to inaccurate results and study conclusions. The proposed drug therapy is the first of its kind. It is a novel dual biological antibody therapy which will act as an anti-viral and anti-inflammatory agent. This project is incredibly time sensitive due to the urgent need for the development of new therapies to tackle the current Covid-19 pandemic. The cell lines, plasmids and antibody sequences needed for the development of this drug are all currently housed at Fusion Antibodies. Additionally, the Belfast location of Fusion Antibodies will aid the logistics of the project in facilitating the rapid delivery of the drug samples for testing in collaborators lab at QUB throughout the production line. This testing needs to happen at regular intervals and is an integral part of the drug development.

https://www.investormeetcompany.com/investor/meeting/interim-results-presentation-1

Just a reminder for anyone that missed it

Listen out for Paul Kerr’s expectation for the value of the Mamalian Library in couple years. !!!

I’ve just bought 15,153 at 1.17. Won’t show for a while.

That’s more cheap shares for me.

Is no one else buying these at these bargain basement prices is it only me.

In response to a new initiative in Germany

BEAT Cov Biotech Emergancy Alliance for Therapies against Covid 19

Fusion Antibodies proud to add our technology and knowledge to the #stopcovid19

The reason for yesterday’s dead market and no support on the bid was a large 20,000 sell at 1.075 late on Tuesday. So now the MM have that stock that they need to clear hence the liquidity on the offer at 116.

But again as soon as that is cleared then any buying activity will push it higher.

Clearly the market makers don’t want to hold any positions long or short for any length of time in this share as it’s too volatile as the free float must be almost zero now.

Hence any good news and light the blue touch paper.

Clearly anyone who wants to build a position should look to take any opportunity they can to buy and tuck the stock away in the bottom draw as and when it becomes available from these small sellers.

Hope this helps.

That news could be early 2021 on neutralising antibodies for Covid.

Paiul Kerr’s Twitter post.

Brilliant work @DeepMind team using #AlphaFold2 it will help companies like @FsnAntibodies provide better engineered antibodies for drug candidates faster. Congratulations ??

https://www.investormeetcompany.com/investor/meeting/interim-results-presentation-1

Register to watch

Trickle might be turning in to a stream

Been a few bargain hunters out today if that trickle turned into a flood then we would move quickly back up.